Sahoo Biswajit, Mane Krantisurya, Panigrahi Manas Kumar, Mishra Sourav Kumar, Barik Sandip Kumar, Majumdar Saroj Kumar Das, Nayak Manoj Kumar, Lohiya Ayush, Swain Phanindra Kumar, Nayak Hemanta Kumar, Das Deepak Kumar, Pitchaimuthu Arunprakash, Muduly Dillip Kumar, Naik Suprava, Gamanagatti Shivanand, Sasmal Prakash Kumar, Kumar Pankaj, Kar Madhabananda
All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India.
Kalyan Singh Super Speciality Cancer Institute, Lucknow, India.
Abdom Radiol (NY). 2025 Jul 25. doi: 10.1007/s00261-025-05140-2.
Percutaneous transhepatic biliary drainage (PTBD) is a widely used palliative intervention to relieve symptoms and reduce bilirubin levels to facilitate further treatments. However, data regarding its clinical outcomes and impact on quality of life (QOL), particularly in the Indian population, are limited. This prospective observational study intends to analyze the clinical outcomes, complication profile, factors affecting the clinical outcomes, and QOL assessment following PTBD in patients with malignant biliary obstruction (MBO).
175 patients with MBO who underwent PTBD between March 2023 and August 2024 were enrolled in the study. The primary outcomes assessed included technical and clinical success following PTBD. The secondary outcomes comprised QOL evaluations using the European Organisation for Research and Treatment of Cancer Quality of Life questionnaire-BIL21, with follow-ups at 1 week, 1 month, and 3 months, as well as an examination of the factors influencing clinical success. Statistical analyses involved descriptive statistics, paired sample t-tests, bivariate and multivariate regression analyses, and Wilcoxon signed-rank tests, with p-values of less than 0.05 considered significant.
Technical success, defined as the correct catheter placement with bile drainage, was achieved in all cases (100%). Clinical success was observed in 81.6% of patients, with a significant reduction in median serum bilirubin from 15.67 mg/dL (IQR 8.91) at baseline to 3.9 mg/dL (IQR 2.9) at 4 weeks (p < 0.001). QOL improved significantly, particularly in eating, jaundice, tiredness, drainage tube, and weight loss scales, as measured at 1 month (p < 0.001). Complications were recorded in 76 (76/152, 50%) of cases, primarily consisting of minor complications such as peri-catheter leakage 52 (52/152, 34.2%) and major complications including cholangitis or sepsis 17(17/152, 11.2%), hemorrhage 2(2/152, 1.3%), and pancreatitis 1(1/152, 0.7%). In the multivariate regression analysis, age (p = 0.035) and liver metastases (p = 0.005) were significantly associated with clinical success. The Kaplan-Meier survival analysis indicated a median survival of 115 days (95% CI, 38.6-191.4, p = 0.025), compared to 46 days (95% CI, 0-103.4, p = 0.025) in the non-successful counterpart.
PTBD is a safe and effective option for managing MBO. Factors such as age at presentation and liver metastases status were found to be significantly associated with the clinical success of PTBD, while ECOG status, level of biliary obstruction, and unilobar or bilobar drainage were not significant. Therefore, it is advisable to consider these factors before proceeding with the PTBD procedure. There is a notable long-term difference in QOL post-PTBD, particularly regarding the jaundice and tiredness scales.
经皮肝穿刺胆道引流术(PTBD)是一种广泛应用的姑息性干预措施,用于缓解症状并降低胆红素水平,以利于进一步治疗。然而,关于其临床结局以及对生活质量(QOL)的影响的数据有限,尤其是在印度人群中。这项前瞻性观察性研究旨在分析恶性胆管梗阻(MBO)患者接受PTBD后的临床结局、并发症情况、影响临床结局的因素以及生活质量评估。
2023年3月至2024年8月期间接受PTBD的175例MBO患者纳入本研究。评估的主要结局包括PTBD后的技术成功和临床成功。次要结局包括使用欧洲癌症研究与治疗组织生活质量问卷-BIL21进行生活质量评估,在1周、1个月和3个月进行随访,以及检查影响临床成功的因素。统计分析包括描述性统计、配对样本t检验、双变量和多变量回归分析以及Wilcoxon符号秩检验,p值小于0.05被认为具有统计学意义。
所有病例(100%)均实现技术成功,即导管放置正确且胆汁引流顺畅。81.6%的患者观察到临床成功,中位血清胆红素从基线时的15.67mg/dL(四分位间距8.91)显著降至4周时的3.9mg/dL(四分位间距2.9)(p<0.001)。生活质量有显著改善,尤其是在1个月时测量的饮食、黄疸、疲劳、引流管和体重减轻量表方面(p<0.001)。76例(76/152,50%)病例记录有并发症,主要包括轻微并发症,如导管周围渗漏52例(52/152,34.2%),以及严重并发症,包括胆管炎或败血症17例(17/152,11.2%)、出血2例(2/152,1.3%)和胰腺炎1例(1/152,0.7%)。在多变量回归分析中,年龄(p=0.035)和肝转移(p=0.005)与临床成功显著相关。Kaplan-Meier生存分析表明,中位生存期为115天(95%置信区间,38.6 - 191.4,p=0.025),而未成功组为46天(95%置信区间,0 - 103.4,p=0.025)。
PTBD是治疗MBO的一种安全有效的选择。发现就诊时年龄和肝转移状态等因素与PTBD的临床成功显著相关,而东部肿瘤协作组(ECOG)状态、胆管梗阻水平以及单叶或双叶引流则无显著关联。因此,在进行PTBD手术前考虑这些因素是明智的。PTBD术后生活质量存在显著的长期差异,尤其是在黄疸和疲劳量表方面。